Scilex Holding Company: Insights from the H.C. Wainwright Conference
Scilex Holding Company to Present at Key Investment Conference
PALO ALTO, Calif. -- Scilex Holding Company (Nasdaq: SCLX), a trailblazer in innovative, non-opioid pain management solutions, is poised to make a significant impact at the 26th Annual H.C. Wainwright Global Investment Conference. The presentation will be led by Jaisim Shah, Chief Executive Officer and President of Scilex, capturing the attention of investors and health professionals alike.
Details on the Presentation
Date and Venue
The conference is scheduled from September 9-11, 2024, held at the prestigious Lotte NY Palace Hotel in New York City. Scilex's presentation will take place on September 11, from 8:00 to 8:30 AM ET, where key updates and future strategies will be discussed.
Scilex: Innovating Pain Management
Scilex Holding Company is committed to revolutionizing pain management with its diverse range of innovative products. Their proprietary offerings include ZTlido®, ELYXYB®, and Gloperba®. ZTlido® is a topical lidocaine product providing relief for neuropathic pain associated with postherpetic neuralgia, while ELYXYB® represents a breakthrough as the only ready-to-use oral solution for acute migraine treatment. Gloperba®, the liquid formulation of colchicine, addresses the preventative needs of patients facing gout flares.
Revolutionizing Treatment Plans
Current and Future Product Candidates
Scilex is not resting on its laurels; it has three promising candidates in its pipeline. SP-102 (SEMDEXA™) is a viscous gel sought for treating lumbosacral radicular pain, having received Fast Track designation from the FDA. Similar forward momentum surrounds SP-103, a next-generation, triple-strength lidocaine formulation designed for chronic neck pain, and SP-104, a unique low-dose naltrexone targeted for fibromyalgia treatment.
Commitment to Innovation
Scilex Holding Company is unwavering in its dedication to developing non-opioid therapies that fulfill unmet medical needs and enhance patient outcomes. Their team continually seeks to expand therapeutic options, addressing pain management in both acute and chronic scenarios with compassion and expertise.
Connecting with Scilex
Scilex remains open to dialogue with investors and interested parties, inviting inquiries about its progress and potential. The team’s efforts are centered on transparency and continued engagement within the health management community.
Frequently Asked Questions
What is the purpose of Scilex Holding Company's presentation at the conference?
The presentation aims to showcase Scilex’s innovative products and discuss future strategies in the non-opioid pain management market.
When and where is the conference taking place?
The conference will take place from September 9-11, 2024, at the Lotte NY Palace Hotel in New York City.
What products does Scilex currently offer?
Scilex offers ZTlido®, ELYXYB®, and Gloperba®, targeting pain management for multiple medical conditions.
What are the new product candidates Scilex is developing?
Scilex is working on SP-102 (SEMDEXA™), SP-103, and SP-104, targeting various types of pain and conditions.
How can investors reach out to Scilex Holding Company?
Investors can contact Scilex through their official email at info@scilexholding.com or visit their website for more information.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.